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exon 18 were rare (3%) in concor-
dance with the majority of published 
studies.3,4,6 In addition, the authors 
confirmed the Asian and occidental 
conclusions that EGFR mutation rate 
was significantly higher in women 
and in never smokers.3,4,6
However, the study presents sev-
eral limitations because of numerous 
biases, and the result presented here 
should be interpreted with caution3:
- The population analyzed was 
not representative for the overall 
Moroccan population; as an exam-
ple, the frequency of EGFR muta-
tion in female patients included 
was 34% (46 of 137), largely higher 
than frequencies showed in Rabat 
and Casablanca registries (the only 
2 registries available in Morocco).1,2 
According to Casablanca registry, 
women with AC represent only 
16% of lung AC and men with AC 
represent 84% of lung AC.1 In fact, 
in Morocco women, lung cancer 
was a relatively rare condition rep-
resenting only 8% to 11.5% of all 
lung cancers versus 33.4% in devel-
oped countries.1,2,7,8 And women 
with lung cancer in Morocco are 
not smoker in the vast majority of 
the case (79%).7
- In another hand, the analysis was 
performed according to specimen 
available in private laboratories 
(Nations-Unies Pathology Center, 
Hassan Pathology Center, and 
Agdal Pathology Center, at Rabat, 
Morocco; and Casapath Pathology 
Center at Casablanca, Morocco.) 
excluding the majority of speci-
men available at the most important 
institutions in Morocco, such as 
the University Hospitals (National 
Institute of Oncology at Rabat, 
Morocco, and Ibn-Rochd University 
Hospital at Casablanca, Morocco).
We do not agree with the author’s 
conclusion that EGFR mutation fre-
quency in Moroccan patients is higher 
than that found in whites, but it is 
the same than that observed in white 
population. By using the frequency 
of EGFR mutation in men (7 of 91 
= 7.7%) and the frequency of EGFR 
mutation in women (22 of 46 = 47.8%) 
calculated from data of the present 
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article and by using Moroccan sta-
tistics (Casablanca registry), we can 
estimate the true frequency of EGFR 
mutation in our population; according 
to Casablanca registry (the most pow-
erful registry), female patients with 
lung AC represent 16% of lung AC 
and male patients with lung AC rep-
resent 84% of lung AC, the frequency 
of EGFR mutation will be approxi-
mately (16 × 47.8/100 + 7.7 × 84/100 
= 7.6% + 6.45%) = 14%. Therefore, 
we suggest that the incidence of 
EGFR mutation in Moroccan patients 
is equivalent than that observed in 
white population, and we encourage 
the Moroccan investigators to conduct 
a multiinstitutional and large study 
including consecutive patients with 
AC diagnosed at the most important 
Cancer Center in Morocco to confirm 
this suggestion and to refine the result 
of the present study.3 
Nabil Ismaili, MD
Rizlane Belbaraka, MD
Department of Medical Oncology 
Oncology Center 
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In Response:
On behalf of the author group, we 
thank Dr. Ismaili for his interest in our 
article Spectrum of EGFR Mutation in 
Lung Adenocarcinoma in Morocco1 and 
his insightful comments.
With regard to his comments, we 
think the following points should be 
clarified. First, our series was a retro-
spective study and therefore some poten-
tial sources of bias cannot be ruled out. 
Despite this, our results provide some 
information about the frequency of epi-
dermal growth factor receptor (EGFR) 
mutation in lung adenocarcinoma in 
Morocco, and as indicated in our article, 
have to be confirmed in larger prospec-
tive studies. Second, data analysis was 
performed according to the availability 
of specimens in private pathology labora-
tories because these laboratories perform 
more than 90% of all tests requested in 
Morocco, and EGFR mutation testing is 
not available for specimens that could be 
found in public institutions.
We do not fully agree with sug-
gestion made by Dr. Ismaili that the inci-
dence of EGFR mutation in Moroccan 
patients would be equivalent than that 
observed in white population. In our 
series, the EGFR mutation rate was 
higher than that found in other studies 
conducted in whites despite similar sex 
distribution.2,3 For example, Rosell et 
al.2, in a large prospective Spanish study, 
reported EGFR mutation in only 16% 
of patients with lung cancer including 
39% of female patients. In such situa-
tion, extrapolation as done by Dr. Ismaili 
should be avoided, and we believe that the 
best way to provide an accurate EGFR 
mutation rate in Moroccan patients is to 
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hazard of death for treatment C. If the 
ratio of hazards r(t)=λ
e
(t)/λ
c
(t) does not 
depend on time t then the proportional 
hazards assumption holds. Denoting 
this ratio by HR we can interpret HR 
= 0.75 (without reference to time) as 
“patients on treatment E have a 25% 
reduced risk of death relative to treat-
ment C.” If we switch the interpretation 
to be in terms of C relative to E then this 
is λ
c
(t)/λ
e
(t)=1/HR, which means that 
the hazard for C is (1/0.75) or 133% 
the hazard of E. Note that [λ
c
(t)–λ
e
(t)]/
λ
e
(t)=1/HR − 1, where λ
c
(t)–λ
e
(t) repre-
sents how much treatment C increases 
the hazard of death compared with E. 
Then 1/HR − 1 = 33% is the percentage 
increase in the hazard of death for treat-
ment C relative to treatment E.
Because survival probabilities 
(OS curves) are an explicit mathematical 
expression of the hazard function, that 
“treatment E reduces the risk (hazard) 
of death” already directly translates into 
prolonged OS for E relative to C. As we 
design trials to assess whether an experi-
mental regimen prolongs OS relative to a 
control, the interpretation given by 1 − HR 
(E versus C) is what is needed.
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conduct a large prospective study (cur-
rently ongoing in our institution).
Finally, we once again thank Dr. 
Ismaili for his thoughtful comments and 
we are grateful to get the opportunity to 
clarify some points from our work. 
Ibrahim Elghissassi, MD 
Hassan Errihani, MD
Medical Oncology Department
National Institute of Oncology
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In Response:
appropriate and is standard throughout 
the statistical and medical literature. The 
interpretation provided by (2), however, 
is not sound and can cause considerable 
miscommunication of study results. 
Statement (2) suggests that treatment 
E extends the survival times of patients 
after treatment E by 33% compared with 
the survival times of patients after treat-
ment C. For example, 1-year OS under 
treatment C is extended to 1.33 years 
under treatment E, 2-year OS extended 
to 2.66 years, and so on. The degree of 
improvement in OS times or probabili-
ties cannot by itself be summarized by a 
single value as survival differences will 
vary across time. Although the HR is 
generally considered the most important 
comprehensive summary of survival 
comparisons, its interpretation should 
not be taken out of context.
The authors’ interpretation 
assumes that survival times follow an 
exponential distribution. In this case, 
when both treatment groups follow expo-
nential distributions, then the ratio of 
medians, m
e
/m
c
 (say), is equal to 1/HR. 
The exponential model, however, should 
not be the basis for general interpreta-
tion. For example, suppose that treat-
ment C survival times follow a Weibull 
model with shape parameter ν and scale 
parameter θ (cf. ref.2), and that the hazard 
function for treatment E is equal to three-
fourths the hazard function for treatment 
C. We note that the exponential model is 
a special case of the Weibull model with 
shape parameter ν=1. Then HR=0.75 
and the ratio of medians is equal to 1/
HR=1.33 if and only if ν=1. However, 
if ν=0.25, for example, then the ratio of 
medians is equal to 3.16, and if ν=4, then 
the ratio is 1.07. These examples illus-
trate the pitfalls of interpreting 1/HR as 
the “increase in survival time.”
Here we clarify that for HR=0.75, 
1 − HR = 0.25 means that “treatment E 
reduces the risk of death by 25% rela-
tive to treatment C,” whereas 1/HR − 1 = 
0.33 means that “treatment C increases 
the risk of death by 33% relative to 
treatment E.” In other words, convert-
ing the interpretation from 1 − HR to 
1/HR − 1 simply changes the reference 
group; from E versus C to C versus E. 
This can be seen from the definition 
of the HR. Let λ
e
 denote the hazard of 
death for treatment E, and λ
c
 denote the 
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In their article, Barraclough et 
al.1 provide important insights into 
the interpretation of hazard ratio 
(HR) estimates from Cox models and 
Kaplan–Meier curves from clinical tri-
als. Unfortunately, the authors provide 
a particular interpretation of the HR, 
which can distort both statistical and 
clinical interpretations. Specifically, 
the authors interpret (see ref.,1 p. 981, 
Box 2) a 0.75 HR for overall survival 
(OS), comparing treatment E (experi-
mental) versus C (control), as either (1) 
a 25% lower risk of death (via 100 × 
(1 − HR)%, denoted 1 − HR), or (2) a 
33% increase in the survival time (via 
100 × (1/HR − 1)%, denoted 1/HR − 1). 
The interpretation provided by (1) is 
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We appreciate the opportunity 
to reply to the letter by Leon et al. 
in response to our article on Hazard 
